Processing

Please wait...

Settings

Settings

1. WO1996005820 - HYPERLIPEMIA REMEDY

Publication Number WO/1996/005820
Publication Date 29.02.1996
International Application No. PCT/JP1995/001486
International Filing Date 26.07.1995
Chapter 2 Demand Filed 16.11.1995
IPC
A61K 31/18 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
16Amides, e.g. hydroxamic acids
18Sulfonamides
A61K 31/195 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19Carboxylic acids, e.g. valproic acid
195having an amino group
A61K 31/277 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
275Nitriles; Isonitriles
277having a ring, e.g. verapamil
A61K 31/381 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
38having sulfur as a ring hetero atom
381having five-membered rings
A61K 31/4152 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
4151,2-Diazoles
4152having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
A61K 31/50 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
50Pyridazines; Hydrogenated pyridazines
CPC
A61K 31/18
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
16Amides, e.g. hydroxamic acids
18Sulfonamides
A61K 31/195
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
19Carboxylic acids, e.g. valproic acid
195having an amino group
A61K 31/277
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
275Nitriles; Isonitriles
277having a ring, e.g. verapamil
A61K 31/381
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
38having sulfur as a ring hetero atom
381having five-membered rings
A61K 31/4152
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
4151,2-Diazoles
4152having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
A61K 31/50
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
50Pyridazines; Hydrogenated pyridazines
Applicants
  • ZERIA PHARMACEUTICAL CO., LTD. [JP/JP]; 10-11, Nihonbashikobunacho Chuo-ku Tokyo 103, JP (AllExceptUS)
  • MERA, Yukinori [JP/JP]; JP (UsOnly)
  • NISHI, Naoki [JP/JP]; JP (UsOnly)
  • KURIMOTO, Tadashi [JP/JP]; JP (UsOnly)
  • SATO, Hiroki [JP/JP]; JP (UsOnly)
Inventors
  • MERA, Yukinori; JP
  • NISHI, Naoki; JP
  • KURIMOTO, Tadashi; JP
  • SATO, Hiroki; JP
Agents
  • ARUGA, Mitsuyuki ; Kyodo Building 3-6, Nihonbashiningyo-cho 1-chome Chuo-ku Tokyo 103, JP
Priority Data
6/22273625.08.1994JP
Publication Language Japanese (JA)
Filing Language Japanese (JA)
Designated States
Title
(EN) HYPERLIPEMIA REMEDY
(FR) MEDICAMENT CONTRE L'HYPERLIPEMIE
Abstract
(EN)
A hyperlipemia remedy containing an indan derivative represented by general formula (1) or a pharmaceutically acceptable salt thereof as the active ingredient; the use of the above compound for the preparation of a hyperlipemia remedy; and a therapeutic method for hyperlipemia using this compound, wherein R1 represents C1-C12 alkyl, benzyl, styryl, naphthyl, optionally substitued phenyl or optionally substituted thienyl; R2 represents carboxy, C1-C4 alkoxycarbonyl or a group represented by formula (a) or (b), Y represents -(CH2)p- (wherein p represents an integer of 0 to 5), -CO-(CH2)q$m(k), -CH(OH)-(CH2)q$m(k) (wherein q represents an integer of 1 to 4, and the symbol $m(k) represents a bond to R2), oxymethylene or vinylene; and n represents an integer of 1 to 4.
(FR)
Médicament contre l'hyperlipémie renfermant un dérivé d'indane représenté par la formule générale (1), ou sel pharmaceutiquement acceptable de ce dérivé utilisé comme principe actif. L'invention porte également sur l'utilisation de ce composé pour l'élaboration d'un médicament contre l'hyperlipémie et sur une méthode thérapeutique contre l'hyperlipémie mettant en ÷uvre ce composé. Dans cette formule, R1 représente C1-C12 alkyle, benzyle, styryle, naphtyle, phényle ou thiényle à substitution facultative; R2 représente carboxy, C1-C4 alcoxycarbonyle ou un groupe représenté par les formules (a) or (b). Dans cette formule, Y représente -(CH2)p- (p correspondant à un entier de 0 à 5), -CO-(CH2)q$m(k), -CH(OH)-(CH2)q$m(k) (q correspondant à un entier de 1 à 5 et le symbole $m(k) représentant une liaison à R2), de l'oxyméthylène ou du vinylène; et n représente un entier de 1 à 4.
Latest bibliographic data on file with the International Bureau